Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19

In this Journal, Rossotti and colleagues provided early data on tocilizumab utility in COVID-191, later confirmed in randomised studies2. Tocilizumab-mediated inhibition of IL-6 signalling can decrease CRP concentrations1, potentially confounding the diagnosis of bacterial co-infections in COVID-19 that occur more frequently following longer hospital stays and admissions to the intensive care unit (ICU)3 –5.
Source: Journal of Infection - Category: Infectious Diseases Authors: Tags: Letter to the Editor Source Type: research